Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linong Ji

Showing results (171-180 of 587) with videos related to

Pageof 59
Sort By:
Diabetes/Metabolism Research and Reviews|November 11, 2017
Low triglyceride as a marker for increased risk of cardiovascular diseases in patients with long-term type 2 diabetes: A cross-sectional survey in ChinaYanfeng Ren, Qian Ren, Juming Lu, et al.
Cardiovascular Diabetology|June 10, 2021
Correction to: SGLT2 inhibitors and lower limb complications: an updated meta-analysisChu Lin, Xingyun Zhu, Xiaoling Cai, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 1, 2018
Insulin Injection Technique in China Compared with the Rest of the WorldZhenqiang Song, Xiaohui Guo, Linong Ji, et al.
Eclinicalmedicine|March 3, 2023
Trends in baseline HbA1c and body-mass index in randomised placebo-controlled trials of type 2 diabetes from 1987 to 2022: a systematic review and meta-analysisSuiyuan Hu, Chu Lin, Xiaoling Cai, et al.
Diabetes, Obesity & Metabolism|September 16, 2024
Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN ChinaLinong Ji, Yibing Lu, Zewei Shen, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 24, 2021
Cost-Effectiveness of Flash Glucose Monitoring for the Management of Patients with Type 1 and Patients with Type 2 Diabetes in ChinaXinran Zhao, Jian Ming, Shuli Qu, et al.
Expert Opinion on Drug Safety|October 29, 2021
Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trialsKeizo Kanasaki, Shen Qu, Fumiko Yamamoto, et al.
European Journal of Preventive Cardiology|April 12, 2026
Dynamic Surveillance of the Cardiovascular Risk and Identification of Treatment Responders in Type 2 Diabetes Using A Machine Learning-Based ModelQi Huang, Xiantong Zou, Edward J Boyko, et al.
Diabetes, Obesity & Metabolism|December 5, 2019
Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naïve people with type 2 diabetes: The EDITION AP randomized controlled trialLinong Ji, Eun Seok Kang, XiaoLin Dong, et al.
Frontiers in Endocrinology|October 31, 2022
Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysisShangyu Chai, Ruya Zhang, Ye Zhang, et al.
Pageof 59

Showing results (171-180 of 587) with videos related to

Sort By:
Pageof 59
Diabetes/Metabolism Research and Reviews|November 11, 2017
Low triglyceride as a marker for increased risk of cardiovascular diseases in patients with long-term type 2 diabetes: A cross-sectional survey in ChinaYanfeng Ren, Qian Ren, Juming Lu, et al.
Cardiovascular Diabetology|June 10, 2021
Correction to: SGLT2 inhibitors and lower limb complications: an updated meta-analysisChu Lin, Xingyun Zhu, Xiaoling Cai, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 1, 2018
Insulin Injection Technique in China Compared with the Rest of the WorldZhenqiang Song, Xiaohui Guo, Linong Ji, et al.
Eclinicalmedicine|March 3, 2023
Trends in baseline HbA1c and body-mass index in randomised placebo-controlled trials of type 2 diabetes from 1987 to 2022: a systematic review and meta-analysisSuiyuan Hu, Chu Lin, Xiaoling Cai, et al.
Diabetes, Obesity & Metabolism|September 16, 2024
Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN ChinaLinong Ji, Yibing Lu, Zewei Shen, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|October 24, 2021
Cost-Effectiveness of Flash Glucose Monitoring for the Management of Patients with Type 1 and Patients with Type 2 Diabetes in ChinaXinran Zhao, Jian Ming, Shuli Qu, et al.
Expert Opinion on Drug Safety|October 29, 2021
Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trialsKeizo Kanasaki, Shen Qu, Fumiko Yamamoto, et al.
European Journal of Preventive Cardiology|April 12, 2026
Dynamic Surveillance of the Cardiovascular Risk and Identification of Treatment Responders in Type 2 Diabetes Using A Machine Learning-Based ModelQi Huang, Xiantong Zou, Edward J Boyko, et al.
Diabetes, Obesity & Metabolism|December 5, 2019
Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naïve people with type 2 diabetes: The EDITION AP randomized controlled trialLinong Ji, Eun Seok Kang, XiaoLin Dong, et al.
Frontiers in Endocrinology|October 31, 2022
Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysisShangyu Chai, Ruya Zhang, Ye Zhang, et al.
Pageof 59